47 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
patients with localized infections
I/C
antibiotics formulated at concentrations between 0 and 6% w/w into bone cements, gentamycin-infused bone cement mixtures
O
eradication or delay of infection onset
P
gynecological cancer
I/C
18 F-FDG PET, management of patients with recurrent gynecological cancers
O
changes in management
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens
P
children
I/C
calcium phosphate (CaP) derivatives, no-intervention/placebo or Fluoride (F) use alone
O
caries preventive and tooth-remineralizing effect
P
373
I/C
Deep learning algorithms, Manual assessment
O
Accuracy, Precision, Recall, F-score, Dice coefficient